Quantum Pharma PLC Appointment of Nominated Adviser (6160Q)

TIDMQP.

RNS Number : 6160Q

Quantum Pharma PLC

01 December 2016

For Immediate Release 1 December 2016

Quantum Pharma Plc

('Quantum', or the 'Company')

Appointment of Nominated Adviser

Quantum Pharma plc (AIM: QP.), the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, announces the appointment of N+1 Singer as the Company's nominated adviser and sole broker with immediate effect.

- Ends -

For further information:

 
 Quantum Pharma Plc 
 Ian Johnson, Chairman                     Tel: [phone] 
  Chris Rigg, CEO and CFO                            279 404 
  Craig Swinhoe, Group Strategic    www.quantumpharmaplc.com 
  Projects Director and Company 
  Secretary 
 N+1 Singer 
  (NOMAD and Broker)                         Tel: +44 (0) 20 
  Sandy Fraser / Nick Owen /                       7496 3000 
  James White                               www.n1singer.com 
 Media enquiries: 
 Buchanan 
 Henry Harrison-Topham / Sophie              Tel: +44 (0) 20 
  Cowles / Steph Watson                            7466 5000 
 [e-mail]           www.buchanan.uk.com 
 

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions: Specials, Niche Pharmaceuticals and Medication Adherence, offering a portfolio of innovative and complementary products and services.

Specials comprises three business units (Quantum Pharmaceutical, UL Medicines and Quantum Aseptics Services). This division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products in response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products). This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose(R) and Biodose Services(R)). This division provides products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose(R), the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect(TM) takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies and provides the Group with exposure to the homecare and supported living sectors of the care pathway, complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPBMBRTMBBJBLF

(END) Dow Jones Newswires

December 01, 2016 02:01 ET (07:01 GMT)